Duration of Complete Response

Biomarker

Related News

ImmunityBio Completes Enrollment in ANKTIVA Plus BCG Trial for Bladder Cancer

Feb 27, 2026

ImmunityBio completed enrollment of 366 patients in its Phase 2 trial of ANKTIVA plus BCG versus BCG alone for BCG-naïve bladder cancer. Interim analysis showed statistically significant improvement in duration of complete response, with the company anticipating a BLA submission by Q4 2026.

ImmunityBio Gains EU Approval for Anktiva Bladder Cancer Therapy, Expands to Saudi Arabia

Feb 21, 2026

ImmunityBio receives conditional EU marketing authorization for Anktiva combination therapy in bladder cancer, covering 33 countries, while establishing distribution partnerships in Saudi Arabia for bladder and lung cancer patients.